| Literature DB >> 29743997 |
Manuel Reyes1, Michael J Reardon1.
Abstract
Transcatheter aortic valve replacement (TAVR) has exploded into medical care for aortic stenosis, thus changing the treatment options for patients. TAVR is currently approved for extreme-risk, high-risk, and intermediate-risk patients with symptomatic severe aortic stenosis, and randomized trials for low-risk patients are underway. This article traces the trajectory of TAVR as a viable option for higher-risk patients and examines current outcomes.Entities:
Keywords: SAVR; TAVR; expandable valve; surgical aortic valve replacement; transcatheter aortic valve replacement
Mesh:
Year: 2017 PMID: 29743997 PMCID: PMC5935196 DOI: 10.14797/mdcj-13-3-126
Source DB: PubMed Journal: Methodist Debakey Cardiovasc J ISSN: 1947-6108